Abstract:Background/Aims: Oxidized low-density lipoprotein (oxLDL) promotes unregulated platelet activation in patients with dyslipidemic disorders. Although oxLDL stimulates activating signaling, researchers have not clearly determined how these events drive accelerated thrombosis. Here, we describe the mechanism by which ROS regulate autophagy during ox-LDL-induced platelet activation by modulating the PI3K/AKT/mTOR signaling pathway. Methods: For in vitro experiments, ox-LDL, the ROS scavenger N-acetylcysteine (NAC), the mTOR inhibitor rapamycin and the autophagy inhibitor 3-MA were used alone or in combination with other compounds to treat platelets. Then, platelet aggregation was evaluated on an aggregometer and platelet adhesion was measured under shear stress. The levels of a platelet activation marker (CD62p) were measured by flow cytometry, reactive oxygen species (ROS) levels were then quantified by measuring DCFH-DA fluorescence intensity via flow cytometry. Nitric oxide (NO) and superoxide (O2·-) levels were determined by the nitric acid deoxidize enzyme method and lucigenin-enhanced chemiluminescence (CL), respectively. Transmission electron microscopy was used to observe the autophagosome formation, immunofluorescence staining was employed to detect LC3 expression and western blotting was used to measure the levels of PI3K/AKT/mTOR pathway- and autophagy-related proteins. Results: Ox-LDL-induced platelets showed a significant increase in platelet aggregation and adhesion, CD62p expression, ROS level and O2·- content, with an elevated LC3II/LC3I ratio and Beclin1 expression, but a dramatic reduction in the levels of p62 and pathway-related proteins (all P < 0.05). However, platelet activation and autophagy were aggravated by the Rapamycin treatment, and decreased following treatment with NAC, 3-MA, or NAC and 3-MA, together with increased activity of the PI3K/AKT/mTOR pathway. Additionally, decreased platelet activation and autophagy were observed in platelets treated with NAC and Rapamycin or Rapamycin and 3-MA compared with platelets treated with Rapamycin alone, suggesting that both NAC and 3-MA reversed the effects of Rapamycin. Conclusion: Inhibition of ROS production may reduce autophagy to suppress ox-LDL-induced platelet activation by activating PI3K/AKT/mTOR pathway.

Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake In Human Umbilical Vein Endothelial Cells Via Mtor/Nf-Kappa B/Lox-1 Pathway

Rapamycin Inhibits Ox-Ldl-induced Inflammation in Human Endothelial Cells in Vitro by Inhibiting the Mtorc2/pkc/c-Fos Pathway

Rapamycin Promotes the Autophagic Degradation of Oxidized Low-Density Lipoprotein in Human Umbilical Vein Endothelial Cells.

MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration.

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production

Rapamycin-mediated CD36 Translational Suppression Contributes to Alleviation of Hepatic Steatosis

Effects of rapamycin on number and activity of endothelial progenitor cells

Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression.

ROS Promote Ox-LDL-Induced Platelet Activation by Up-Regulating Autophagy Through the Inhibition of the PI3K/AKT/mTOR Pathway

Rapamycin attenuates endothelial apoptosis induced by low shear stress via mTOR and sestrin1 related redox regulation.

Rapamycin Promotes Expansion of Cd4+Cd25+Foxp3+Regulatory T Cells by Modulating Fatty Acid Metabolism?

Rapamycin Directly Activates Lysosomal Mucolipin TRP Channels Independent of Mtor

Rapamycin Inhibits Expression of Elongation of Very-Long-Chain Fatty Acids 1 and Synthesis of Docosahexaenoic Acid in Bovine Mammary Epithelial Cells

[Autophagy of Human Vascular Endothelial Cells by Oxidized Low-Density Lipoprotein: Involvement of Oxidative Stress but No Oxidized Low Density Lipoprotein-1].

Rapamycin Inhibits Osteoclastogenesis and Prevents LPS-Induced Alveolar Bone Loss by Oxidative Stress Suppression

NEAT1/hsa-miR-372-3p axis participates in rapamycin-induced lipid metabolic disorder.

Ox-LDL Induces Endothelial Cell Apoptosis Via the LOX-1-dependent Endoplasmic Reticulum Stress Pathway.

Mannose-binding lectin reduces oxidized low-density lipoprotein induced vascular endothelial cells injury by modulating autophagy via LOX1

Resveratrol Inhibits Inflammatory Responses Via The Mammalian Target Of Rapamycin Signaling Pathway In Cultured Lps-Stimulated Microglial Cells

Rapamycin-Loaded Biomimetic Nanoparticles Reverse Vascular Inflammation